Neuromodulation Devices Market Will Reach $9.3 Billion In 2020, According To Visiongain’s New Analysis

10 September 2018
Pharma

An updated report by visiongain forecasts that overall sales of neuromodulation devices will reach $9.3bn worldwide in 2020. That sales growth will continue through to 2026, aided by advances in that medical device technology and rising needs for treating human neurological disorders. Those revenue predictions and others appear in Neuromodulation Devices Report 2016-2026: Revenue Forecasts for Deep Brain Stimulation, Spinal Cord, Vagus Nerve, Sacral Nerve and Gastric Electrical Applications. In March 2016 that updated report received publication, adding to a long-running catalogue of healthcare studies.

Visiongain is a business information publisher and consultancy in London, UK. Its purpose is to help organisations understand commercial potentials of industries and markets in healthcare and other fields. Those works include off-the-shelf reports and custom research.

The new investigation assesses events, prospects and sales opportunities shaping the development, production and marketing of neuromodulation devices. The updated study shows multilevel revenue forecasting and qualitative assessments. That work also explores activities of companies developing, producing and selling neuromodulation medical devices, assessing their potentials. That market holds many technological and commercial opportunities from 2016, including rising sales in developed and emerging countries.

Visiongain predicts the neuromodulation devices industry will continue to expand its revenues from 2016 to 2026. That sales expansion is driven by ageing populations and the increasing prevalence of chronic neurological disorders. Adding to this will be the growing demand from emerging national markets, as their economies prosper and rising expenditure on healthcare increases the demand and ability to pay for those neurological treatments.

The updated study shows how demand for neuromodulation devices will change owing to political and economic changes in developed and developing countries. Furthermore the shifts in market share of the submarkets are shown, assessing developments, opportunities and prospects for neuromodulation devices technology.

Aanchal Verma, a healthcare industry analyst in visiongain, said: “The prevalence of age-related diseases and chronic neurological disorders is increasing globally. Neuromodulation devices provide promising treatments for illnesses including chronic pain, epilepsy, Parkinson’s disease, depression and incontinence. The future of the neuromodulation devices market will be based on innovative techniques to expand the application of those devices and treat a wider range of neurological diseases.

“Demand for neuromodulation devices is set to increase rapidly in the near future, owing to lifestyle changes and an ageing population that is predisposed to chronic neurological diseases. Furthermore, the convenient and non-invasive characteristics of the devices. along with their improved affordability in healthcare systems in emerging economies, will continue to fuel the demand for neuromodulation devices globally.”

Visiongain’s new investigation shows revenue predictions at overall world market, submarket and national level.

That study gives individual revenue predictions to 2026 for six neuromodulation devices submarkets at world level:

• Spinal cord stimulation (SCS)
• Deep brain stimulation (DBS)
• Vagus/vagal nerve stimulation (VNS)
• Sacral nerve stimulation (SNS)
• Gastric electrical stimulation (GES)
• Other techniques (grouped forecast), including trigeminal nerve stimulation, cochlear implants, transcranial magnetic stimulation, transcranial direct current stimulation and ultrasonic neuromodulation.

Visiongain’s analysis also shows prospects for those medical device sales in developed and developing regions. Revenue forecasts to 2026 for 11 countries appear:

• United States
• Japan
• Germany, France, United Kingdom, Italy and Spain (EU5 group)
• Brazil, Russia, India and China (BRIC countries).

From 2016, large manufacturers of medical devices and smaller companies can prosper in that market. In particular the new study discusses performances, activities and potentials of four leading companies:

• Medtronic
• Boston Scientific
• St. Jude Medical
• Cyberonics.

Discussions of rising companies also appear. The survey also shows visiongain’s interviews with the International Neuromodulation Society and NeuroSigma.

Neuromodulation Devices Report 2016-2026: Revenue Forecasts for Deep Brain Stimulation, Spinal Cord, Vagus Nerve, Sacral Nerve and Gastric Electrical Applications adds to visiongain’s reports on industries and markets in healthcare. That portfolio covers pharmaceuticals, medical devices, diagnostics and outsourced services, including contract research (CROs), manufacturing (CMOs) and selling (CSOs).

Supporting information

About Visiongain’s Healthcare Reports
Visiongain is a business information publisher and consultancy in London, UK. Its purpose is to help organisations understand commercial potentials of industries and markets in healthcare and other fields. Those works include off-the-shelf reports and custom research.

Visiongain's healthcare reports use primary and secondary research. Those investigations show revenue forecasts, driving and restraining forces and technological developments (R&D). That work also gives geographical breakdowns of the world market under study. Analyses are original, benefiting from analysts consulting authorities in industries, academia, medical practice and other positions. The authors also use visiongain’s proprietary work, commercial data, companies’ reports, business news and trade articles, public health data, policy documents and other sources. Visiongain’s in-house analysts, based in the UK, do primary research by email and telephone interviewing.

Their reports contain quantitative and qualitative analyses of markets’ present and future. Although those studies focus on industries and markets, they include medical and technical information. Their sales forecasting assesses the size and effects of driving and restraining forces on industries, companies and technologies, to predict revenues as 10-year forecasts. Visiongain’s analysts develop forecasts from an understanding of markets, products, epidemiology and other knowledge. They show that data in reports rich in tables, charts and discussions.

Each year visiongain publishes dozens of studies on healthcare markets. That range of reports explains prospects for developers, producers and sellers of pharmaceuticals, diagnostic tools, medical devices and contract services. Each year new studies and updates appear, serving the needs of leading companies.

Recent News

“In Vitro Diagnostics (IVD) market set to grow to $91bn by 2024” says new Visiongain report

In recent years, the IVD market has experienced increased consolidation among industry participants, with significant merger and acquisition (M&A) activity, especially among larger companies as they diversify and manoeuvre for stronger positions.

14 May 2019

Read

“Indian Pharmaceutical market set to grow to $71bn by 2024” says new Visiongain report

Expected increases in the level of healthcare coverage will allow greater proportion of the population to be able to afford medical care, which is still mostly paid for out-of-pocket by patients, as a greater amount of people have health insurance to cover their medical expenses.

09 May 2019

Read

“Global mRNA Vaccines and Therapeutics market set to grow to $5.5bn by 2024” says new Visiongain

The major drivers supporting the growth of the mRNA Vaccines and Therapeutics Market are rising adoption of personalized medicine for effective treatment, advantages offered by mRNA-based products, and rising funding by pharmaceutical companies and government organizations.

07 May 2019

Read

“Global Oncology Drugs market set to grow to $173bn by 2024” says new Visiongain report

The cancer treating drugs market will continue to grow over the next ten years.

03 May 2019

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever
WOOCS 2.2.1